AlzeCure Pharma AB (ALZCUR) AI Stock Analysis

• Market Cap: €301.08M
• Dividend Yield: N/A
• Average Volume (3M): 168.14K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.31
• Revenue Growth: N/A
• EPS Growth: 22.73%
• Country: SE
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.10
• Shares Outstanding: 114,914,450
• 10 Day Avg. Volume: 109,953
• 30 Day Avg. Volume: 168,138
• PEG Ratio: 0.11
• Price to Book (P/B): 3.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

AlzeCure Pharma AB's overall score is impacted by its pre-revenue status, leading to financial losses despite a strong equity position without debt. The positive stock price trend provides some optimism, but the negative valuation metrics due to the absence of earnings weigh negatively. The company's future hinges on successful product development and revenue generation.

AlzeCure Pharma AB Business Overview & Revenue Model

Company Description

AlzeCure Pharma AB (ALZCUR) is a Swedish pharmaceutical company that focuses on developing innovative therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease and pain management. The company operates in the biotechnology sector, leveraging its expertise in neuroscience to advance its pipeline of drug candidates. AlzeCure's core products include a range of proprietary small molecule drugs that target key pathways involved in neurodegeneration.

How the Company Makes Money

AlzeCure Pharma AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company invests in research and development to advance its drug pipeline towards clinical trials, seeking partnerships and collaborations with larger pharmaceutical firms to co-develop or license its technologies. Licensing agreements and milestone payments from such partnerships contribute significantly to the company's revenue. Additionally, AlzeCure may receive funding from grants and public or private investments to support its ongoing research efforts. The strategic focus on addressing unmet medical needs in neurodegenerative diseases positions AlzeCure to potentially capture market share upon successful drug approval and commercialization.

AlzeCure Pharma AB Financial Statement Overview

Summary

AlzeCure Pharma AB is in a typical pre-revenue pharmaceutical phase, with no revenues but high R&D expenses leading to financial losses. The balance sheet remains debt-free with substantial equity but is gradually depleting. Cash flow management is reliant on external financing, highlighting the need for successful product development and eventual revenue generation.

Income Statement

AlzeCure Pharma AB has consistently reported zero revenue over the years, indicating the company is still in pre-revenue stages, typical of many pharmaceutical companies awaiting product approval. However, this results in substantial operating losses, with negative EBIT and net income figures, which highlight the financial strain of ongoing operations without income.

Balance Sheet

The company's balance sheet shows a strong equity position, with no debt reported, leading to a healthy equity ratio. However, the consistent decline in total assets and equity over time could pose a risk if revenue generation does not materialize soon.

Cash Flow

AlzeCure Pharma AB has negative free cash flow, indicating cash outflows exceed cash generated, a common scenario for R&D-focused pharmaceutical firms. While operating cash flow has shown some improvement, the company heavily relies on financing activities to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-146.00K	-293.00K	-476.00K	-570.00K	-576.00K	-495.00K
EBITDA	-36.43M	-35.70M	-37.87M	-55.67M	-77.20M	-70.87M
Net Income	-36.62M	-35.23M	-37.17M	-56.04M	-77.78M	-71.37M
Balance Sheet
Total Assets	16.39M	34.44M	32.00M	70.84M	45.65M	117.83M
Cash, Cash Equivalents and Short-Term Investments	12.58M	31.50M	29.10M	25.58M	41.74M	112.43M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	10.05M	8.25M	8.23M	10.35M	12.67M	7.07M
Stockholders Equity	6.34M	26.18M	23.77M	60.48M	32.97M	110.75M
Cash Flow
Free Cash Flow	-26.69M	-35.25M	3.06M	-99.91M	-70.69M	-70.18M
Operating Cash Flow	-26.57M	-35.12M	3.06M	-99.91M	-70.64M	-69.51M
Investing Cash Flow	-124.00K	-124.00K	7.00K	0.00	-54.00K	-671.00K
Financing Cash Flow	3.59M	37.65M	459.00K	83.75M	0.00	114.00K

AlzeCure Pharma AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZCUR, the sentiment is Neutral. The current price of 2.52 is below the 20-day moving average (MA) of 2.81, below the 50-day MA of 3.34, and above the 200-day MA of 2.45, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 43.17 is Neutral, neither overbought nor oversold. The STOCH value of 54.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ALZCUR.

AlzeCure Pharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALZCUR	47 Neutral	€301.08M	―	-161.07%	―	―	22.73%
ENZY	41 Neutral	kr526.74M	―	―	―	11.87%	26.50%